My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.09 -1.82 (-6.30%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection ↗

September 19, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 07, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Recap: Beam Therapeutics Q2 Earnings ↗

August 09, 2022

Beam Therapeutics (NASDAQ:BEAM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses ↗

August 01, 2022

The company didn't identify the reason behind the clinical hold in cancer treatment.

Via Investor's Business Daily

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗

August 29, 2022

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗

August 25, 2022

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.

Via Benzinga

5 Cathie Wood Stocks Signaling “The Bear Market Is Over” ↗

August 22, 2022

These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.

Via InvestorPlace

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗

August 17, 2022

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 04, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

August 03, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

August 02, 2022

From The Schall Law Firm

Via Business Wire

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Why Is Target (TGT) Stock in the Spotlight Today? ↗

August 01, 2022

Target (TGT) stock is in the news today as investors react to a new note from Jefferies that gives the retail company flak.

Via InvestorPlace

Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News ↗

August 01, 2022

Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs.

Via InvestorPlace

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 01, 2022

Via Benzinga

Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study ↗

August 01, 2022

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of...

Via Benzinga

Will a Recession Cause a Housing Crash in 2022? ↗

July 27, 2022

For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 26, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage ↗

July 18, 2022

Via Benzinga

Hold Pfizer Today With Catalysts for Further Growth Tomorrow

July 18, 2022

Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.

Via MarketBeat

The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol ↗

July 12, 2022

This could offer an improvement over CRISPR, which requires cutting DNA.

Via Investor's Business Daily

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.